Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 213

1.

Induction of protective CD4+ T cell-mediated immunity by a Leishmania peptide delivered in recombinant influenza viruses.

Kedzierska K, Curtis JM, Valkenburg SA, Hatton LA, Kiu H, Doherty PC, Kedzierski L.

PLoS One. 2012;7(3):e33161. doi: 10.1371/journal.pone.0033161. Epub 2012 Mar 21.

2.

TLR1/2 activation during heterologous prime-boost vaccination (DNA-MVA) enhances CD8+ T Cell responses providing protection against Leishmania (Viannia).

Jayakumar A, Castilho TM, Park E, Goldsmith-Pestana K, Blackwell JM, McMahon-Pratt D.

PLoS Negl Trop Dis. 2011 Jun;5(6):e1204. doi: 10.1371/journal.pntd.0001204. Epub 2011 Jun 14.

3.

Intradermal NKT cell activation during DNA priming in heterologous prime-boost vaccination enhances T cell responses and protection against Leishmania.

Dondji B, Deak E, Goldsmith-Pestana K, Perez-Jimenez E, Esteban M, Miyake S, Yamamura T, McMahon-Pratt D.

Eur J Immunol. 2008 Mar;38(3):706-19. doi: 10.1002/eji.200737660.

4.
5.
6.

Cationic solid-lipid nanoparticles are as efficient as electroporation in DNA vaccination against visceral leishmaniasis in mice.

Saljoughian N, Zahedifard F, Doroud D, Doustdari F, Vasei M, Papadopoulou B, Rafati S.

Parasite Immunol. 2013 Dec;35(12):397-408. doi: 10.1111/pim.12042.

7.

Requirements for the maintenance of Th1 immunity in vivo following DNA vaccination: a potential immunoregulatory role for CD8+ T cells.

Gurunathan S, Stobie L, Prussin C, Sacks DL, Glaichenhaus N, Iwasaki A, Fowell DJ, Locksley RM, Chang JT, Wu CY, Seder RA.

J Immunol. 2000 Jul 15;165(2):915-24. Erratum in: J Immunol 2000 Sep 15;165(6):following 3526.

8.
9.

DNA based vaccination with a cocktail of plasmids encoding immunodominant Leishmania (Leishmania) major antigens confers full protection in BALB/c mice.

Ahmed SB, Touihri L, Chtourou Y, Dellagi K, Bahloul C.

Vaccine. 2009 Jan 1;27(1):99-106. doi: 10.1016/j.vaccine.2008.10.013. Epub 2008 Oct 23.

PMID:
18951941
10.

High quality long-term CD4+ and CD8+ effector memory populations stimulated by DNA-LACK/MVA-LACK regimen in Leishmania major BALB/c model of infection.

Sánchez-Sampedro L, Gómez CE, Mejías-Pérez E, Sorzano CO, Esteban M.

PLoS One. 2012;7(6):e38859. doi: 10.1371/journal.pone.0038859. Epub 2012 Jun 8.

11.

Evaluation of immune responses and protection induced by A2 and nucleoside hydrolase (NH) DNA vaccines against Leishmania chagasi and Leishmania amazonensis experimental infections.

Zanin FH, Coelho EA, Tavares CA, Marques-da-Silva EA, Silva Costa MM, Rezende SA, Gazzinelli RT, Fernandes AP.

Microbes Infect. 2007 Jul;9(9):1070-7. Epub 2007 May 16.

PMID:
17644455
12.
13.

A prime/boost DNA/Modified vaccinia virus Ankara vaccine expressing recombinant Leishmania DNA encoding TRYP is safe and immunogenic in outbred dogs, the reservoir of zoonotic visceral leishmaniasis.

Carson C, Antoniou M, Ruiz-Argüello MB, Alcami A, Christodoulou V, Messaritakis I, Blackwell JM, Courtenay O.

Vaccine. 2009 Feb 11;27(7):1080-6. doi: 10.1016/j.vaccine.2008.11.094. Epub 2008 Dec 16.

14.

Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with Leishmania major.

Gurunathan S, Sacks DL, Brown DR, Reiner SL, Charest H, Glaichenhaus N, Seder RA.

J Exp Med. 1997 Oct 6;186(7):1137-47.

15.
16.

Epitope mapping and protective immunity elicited by adenovirus expressing the Leishmania amastigote specific A2 antigen: correlation with IFN-gamma and cytolytic activity by CD8+ T cells.

Resende DM, Caetano BC, Dutra MS, Penido ML, Abrantes CF, Verly RM, Resende JM, Piló-Veloso D, Rezende SA, Bruna-Romero O, Fernandes AP, Gazzinelli RT.

Vaccine. 2008 Aug 18;26(35):4585-93. doi: 10.1016/j.vaccine.2008.05.091. Epub 2008 Jun 25.

PMID:
18588933
17.
18.

Immune responses induced by the Leishmania (Leishmania) donovani A2 antigen, but not by the LACK antigen, are protective against experimental Leishmania (Leishmania) amazonensis infection.

Coelho EA, Tavares CA, Carvalho FA, Chaves KF, Teixeira KN, Rodrigues RC, Charest H, Matlashewski G, Gazzinelli RT, Fernandes AP.

Infect Immun. 2003 Jul;71(7):3988-94.

20.

Oral immunization using live Lactococcus lactis co-expressing LACK and IL-12 protects BALB/c mice against Leishmania major infection.

Hugentobler F, Di Roberto RB, Gillard J, Cousineau B.

Vaccine. 2012 Aug 24;30(39):5726-32. doi: 10.1016/j.vaccine.2012.07.004. Epub 2012 Jul 17.

PMID:
22814408

Supplemental Content

Support Center